Cardiff Oncology, Inc. - 8-K Filing
Cardiff Oncology increases authorized common stock to 300 million shares and appoints Dr. Leila Alland as interim Chief Medical Officer. (Items: 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year On October 22, 2026, the Company filed a Certificate of Amendment to, 7.01 Regulation FD Disclosure)